Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
高级管理人员任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel, specifically the appointment of Mr. Zhang Bin as the company secretary. It includes details about the appointment, qualifications, and compliance with relevant laws and company regulations. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the appointment. The document is clearly about management changes and not about financial performance or other report types.
2025-04-24 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as an "年度报告" which translates to "Annual Report" and covers the full fiscal year 2024 (January 1 to December 31, 2024). It includes comprehensive sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, internal controls, and financial accounting reports. The document contains detailed financial figures, quarterly data, management analysis, and audit information including a standard unqualified audit opinion from a CPA firm. The length is substantial (15,000 characters) and it is not merely an announcement or a certification. The content matches the definition of an official yearly report covering company activity and full financial performance, which corresponds to the Annual Report (10-K) category. FY 2024
2025-04-24 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the third meeting of the fourth board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results related to the election of an audit committee member. There is no financial data, no detailed report, and no mention of an annual or interim report. The document is a formal announcement of board/management decisions and changes, specifically about the board's audit committee composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board meeting resolutions, not a full report or financial disclosure.
2025-03-20 Chinese
关于补选第四届董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the replacement of a member of the company's fourth board of directors' audit committee. It details the resignation of a director and the subsequent election of a new audit committee member. The content focuses on board/management changes and governance structure adjustments. There are no financial statements, earnings data, or report publications referenced. The document is not a full report but an announcement of a board/management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and specific to management changes, confirming this classification.
2025-03-20 Chinese
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 Annual Performance Express Report" and contains preliminary financial data for the full year 2024, including revenue, profit, net assets, and earnings per share. It explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the 2024 Annual Report. The document includes detailed financial metrics and explanations of performance changes, but it is relatively short (1956 characters) and is described as a "performance express report" (业绩快报), which in Chinese regulatory filings typically corresponds to an Earnings Release (ER) or preliminary earnings announcement rather than a full Annual Report (10-K). It does not contain full audited financial statements or comprehensive management discussion and analysis that would be expected in a full Annual Report. The document also includes a risk warning about the preliminary nature of the data, which is typical for earnings releases. Therefore, the document is best classified as an Earnings Release (ER). FY 2024
2025-02-26 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2025 first extraordinary shareholders' meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, agenda, voting results, and legal opinions. The key content is the approval of a board director nomination and related board changes. There are no financial statements or detailed financial performance data. The document is a formal announcement of voting results from a shareholders' meeting, specifically about board member appointment. This matches the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is short (2081 characters), consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2025-02-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.